Bausch, 2 Others Settle Diabetes Drug Reverse Payment Class Action For $300M

Mealey's (September 14, 2021, 3:33 PM EDT) -- SAN FRANCISCO — Four direct purchasers of a diabetes drug on Sept. 8 filed a motion asking a California federal court to grant preliminary approval to a $300 million antitrust class...
To view the full article, register now.